Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
Case Reports in Psychiatry, 2021 This case outlines recurrent neutropenia after fourteen years of successful clozapine use. The patient has a diagnosis of treatment-resistant schizophrenia which has been complicated by sensitivity to side effects of haloperidol and past failure of ...
Eimear O’ Neill +3 more
doaj +1 more source
Proceedings of the biosimilars workshop at the International Symposium on Oncology Pharmacy Practice 2019. [PDF]
, 2020 The International Society of Oncology Pharmacy Practitioners organized a workshop to create learning opportunities on biosimilars in pharmacy practice on 10 October 2019.
Chan, Alexandre, Ke, Yu, Tan, Chia Jie
core
82: Severe Hemorrhagic Cystitis (HC) After Allogeneic Hematopoeitic Stem Cell Transplantation (HSCT): Incidence and Risk Factors [PDF]
, 2008 With the purpose to investigate the radio emission of new ultracool objects, we carried out a targeted search in the recently discovered system VHS J125601.92$-$125723.9 (hereafter VHS 1256$-$1257); this system is composed by an equal-mass M7.5 binary ...
Azulay, R. +6 more
core +2 more sources
Health Science Reports, Volume 9, Issue 4, April 2026.ABSTRACT Background and Aims The growth and spread of breast carcinoma are influenced by genetic factors. Diverse forms of cancer have been reported to display multiple subtypes of the microRNA gene. Therefore, the current study aimed to explore the connection between the miR‐218‐2 (rs11134527) and breast cancer risk.
A. M. Shamim +5 more
wiley +1 more source
Acta Medica Indonesiana, 2022 Background: Myelosuppressive effects of chemotherapy for breast cancer treatment may trigger chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Filgrastim has been widely used as prophylaxis against CIN and FN.
Ami Ashariati +9 more
doaj +2 more sources
Haematologica, 2007 Twenty-five elderly patients with oligoblastic acute myeloid leukemia (AML) received subcutaneous granulocyte colony-stimulating factor (filgrastim) in addition to supportive care.
Anna Maria Pelizzari +8 more
doaj +1 more source
Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review [PDF]
, 2016 The adoption of primary (PP) versus secondary prophylaxis (SP) of febrile neutropenia (FN), with granulocyte colony-stimulating factors (G-CSF), for adjuvant chemotherapy (AC) regimens in breast cancer (BC) could be affected by its “value for money ...
A Briggs +31 more
core +1 more source
Peripheral blood progenitor cell transplantation mobilised by r-metHuG-CSF (filgrastim); a less costly alternative to autologous bone marrow transplantation [PDF]
, 1994 In a retrospective study, we calculated the treatment costs of 63 patients who received either autologous bone marrow transplantation (ABMT) with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) (filgrastim) (n=13) or without r ...
Richel, D.J. (Dirk) +2 more
core +7 more sources
Immunity, Inflammation and Disease, Volume 14, Issue 4, April 2026.ABSTRACT Background We conducted this study to evaluate the impact of serum inflammatory markers and histopathological features on prognosis in metastatic hormone receptor positive breast cancer patients treated with first line CDK4/6i (cyclin‐dependent kinase inhibitors).
Nilufer Bulut +3 more
wiley +1 more source
Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK) [PDF]
Introduction: We report a cost-effectiveness evaluation of granulocyte colony-stimulating factors (G-CSFs) for prevention of febrile neutropenia (FN) following chemotherapy for non-Hodgkin’s lymphoma (NHL) in the United Kingdom (UK).
Akehurst, R. +3 more
core +3 more sources